EEWOWW is an online personal knowledge management tool. Click to find out more!
Updated in 2018/12/11 下午 06:46:52      Viewed: 111 times      (Journal Article)
Clinical cancer research : an official journal of the American Association for Cancer Research 21 (19): 4384-90 (2015)

PET/CT Improves the Definition of Complete Response and Allows to Detect Otherwise Unidentifiable Skeletal Progression in Multiple Myeloma.

Elena Zamagni , Cristina Nanni , Katia Mancuso , Paola Tacchetti , Annalisa Pezzi , Lucia Pantani , Beatrice Zannetti , Ilaria Rambaldi , Annamaria Brioli , Serena Rocchi , Carolina Terragna , Marina Martello , Giulia Marzocchi , Enrica Borsi , Ilaria Rizzello , Stefano Fanti , Michele Cavo
To evaluate the role of 18F-FDG PET/CT in 282 symptomatic multiple myeloma patients treated up-front between 2002 and 2012.All patients were studied by PET/CT at baseline, during posttreatment follow-up, and at the time of relapse. Their median duration of follow-up was 67 months.Forty-two percent of the patients at diagnosis had >3 focal lesions, and in 50% SUVmax was >4.2; extramedullary disease was present in 5%. On multivariate analysis, ISS stage 3, SUVmax >4.2, and failure to achieve best complete response (CR) were the leading factors independently associated with shorter progression-free survival (PFS) and overall survival (OS). These 3 variables were used to construct a prognostic scoring system based on the number of risk factors. After treatment, PET/CT negativity (PET-neg) was observed in 70% of patients, whereas conventionally defined CR was achieved in 53%. Attainment of PET-neg favorably influenced PFS and OS. PET-neg was an independent predictor of prolonged PFS and OS for patients with conventionally defined CR. Sixty-three percent of patients experienced relapse or progression; in 12%, skeletal progression was exclusively detected by systematic PET/CT performed during follow-up. A multivariate analysis revealed that persistence of SUVmax >4.2 following first-line treatment was independently associated with exclusive PET/CT progression.PET/CT combined with ISS stage and achievement or not of CR on first-line therapy sorted patients into different prognostic groups. PET/CT led to a more careful evaluation of CR. Finally, in patients with persistent high glucose metabolism after first-line treatment, PET/CT can be recommended during follow-up, to screen for otherwise unidentifiable progression.
DOI: 10.1158/1078-0432.CCR-15-0396      ISSN: 1078-0432